A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
← catalyst calendarNCT07123454 · readout in 559 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
91estimated
Sites
22
Countries
Australia, China, Italy +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-24 | actual | When the study began enrolling |
| Primary completion | 2028-03-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- B-cell Non-Hodgkin Lymphoma
Intervention
- Drug: AZD4512
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with dose-limiting toxicities (DLTs)
measured Up to 4 weeks
Frequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)
measured From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Frequency of SAEs/AEs leading to discontinuation of AZD4512
measured From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Number of participants with clinically significant alterations in vitals signs and abnormal laboratory parameters
measured From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed